A trial to evaluate the efficacy and safety of CLR-1404-I-131 in patients with head and neck cancer

Trial Profile

A trial to evaluate the efficacy and safety of CLR-1404-I-131 in patients with head and neck cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2016

At a glance

  • Drugs CLR 1404 I-131
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2016 New trial record
    • 12 Sep 2016 According to a Cellectar Biosciences media release, this trial will be conducted by the University of Wisconsin, as part of a Specialized Program of Research Excellence (SPORE) grant of $US12 million, awarded by the National Cancer Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top